Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor
Reexamination Certificate
2002-05-08
2004-08-10
Leary, Louise N. (Department: 1654)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving blood clotting factor
C435S004000, C435S968000
Reexamination Certificate
active
06773896
ABSTRACT:
FIELD OF THE INVENTION
The present invention generally provides a method of measuring the biological activity of Coagulation Factor VIIa (Factor VIIa). Specifically, the present invention provides a method for directly measuring the activity of Factor VIIa in a plasma sample. More specifically, the present invention provides a method for utilizing Factor VIIa activity as a bio-marker to monitor Factor VIIa inhibition to screen compounds which are able to inhibit the biological activity of Factor VIIa.
BACKGROUND OF THE INVENTION
In the coagulation cascade, Factor VII plays an important role in clot formation. Factor VII is activated by tissue factor (TF) to form Factor VIIa. As one of its functions, Factor VIIa catalyzes the activation of Factor X to Factor Xa which leads to clot formation.
The TF/VIIa complex is thought to play a key role in thrombogenesis in patients with acute coronary syndromes. Therefore, Factor VIIa is an attractive target for antithrombotic therapy. Because Factor VIIa inhibitors are attractive therapeutic agents, a number of such compounds are under scientific evaluation in clinical development.
Methods for detecting the bioactivity of Factor VIIa inhibitors in plasma are essential for identifying and developing Factor VIIa inhibitors. Prior art methods for measuring Factor VIIa in plasma include the use of truncated tissue factor agents as disclosed in U.S. Pat. Nos. 5,472,850; 5,741,658 or indirect, 2-stage assays which are based on the conversion of Factor X to Factor Xa as catalyzed by Factor VII to provide an indirect measure of Factor VIIa activity and are disclosed in the COASET® method (Chromogenix AB, Mölndal, Sweden). Since the COASET® method involves the cleavage of a Factor Xa chromogenic substrate following the activation of Factor X, this method does not provide a direct measure of Factor VIIa activity.
Accordingly, it would be both desirable and advantageous to have a plasma-based, direct (1-step) Factor VIa activity assay which can be utilized as an ex vivo plasma bio-marker assay for obtaining accurate Factor VII bioactivity measurements and also for use in screening compounds for their ability to inhibit Factor VIIa in vivo.
SUMMARY OF THE INVENTION
The present invention provides a method for directly measuring the activity of Coagulation Factor VIIa (Factor VIIa) in a plasma sample. The method comprises the step of combining a quantity of a plasma sample with a solution comprising a buffer, Factor VII, and a detectable Factor VIIa substrate, and then detecting the amount of the detectable substrate catalyzed to determine the activity of Factor VIIa in the sample.
The present invention also discloses a method for determining whether a compound is useful for inhibiting Factor VIIa biological activity.
REFERENCES:
patent: 5399487 (1995-03-01), Butenas et al.
patent: 5472850 (1995-12-01), Morrissey
patent: 5741658 (1998-04-01), Morrissey
patent: 5750358 (1998-05-01), Morrissey
patent: 6100050 (2000-08-01), Hemker et al.
patent: 2002/0168700 (2002-11-01), Chi et al.
patent: 0641443 (1999-10-01), None
patent: 2009326 (2002-11-01), None
patent: 9206711 (1992-04-01), None
patent: 9218870 (1992-10-01), None
patent: 9405328 (1994-03-01), None
patent: 9407515 (1994-04-01), None
patent: 9719357 (1997-05-01), None
patent: 9947699 (1999-09-01), None
patent: 0030646 (2000-06-01), None
Sabharwal et al, J. of Biological Chemistry, V. 270(26), pp 15523-30, (Jun. 1995), (Abstract Only).*
Seligsohn et al., “Coupled Amidolytic Assay for Factor VII: Its Use With a Clotting Assay to Determine the Activity State of Factor VII”,Blood, vol. 52, No. 5, 1978, pp. 978-988.
Kario et al., “The strong positive correlation between factor VII clotting activity using bovine thromboplastin and the activated factor VII level”,Thrombosis and haemostasis, vol. 73, No. 3, 1995, pp. 429-434.
Jeske et al., “Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations”,Blood coagulation&fibrinolysis, 6 Suppl 1, 1995, pp. 573-580.
Hawthorne et al., “Isolation and characterization of recombinant anncain V expressed in Saccharortisyces cerevisine”,Journal of Biotechnology, vol. 36, No. 2, 1994, pp. 129-143.
Chabbat et al., “Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex”,Thrombosis Research, vol. 73, No. 3, 1993, pp. 205-215.
Sandset et al., “Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol”,Blood coagulation&fibrinolysis, vol. 2, No. 3, 1991, pp. 425-433.
Kumar et al., “Identification of molecular sites on factor VII which mediate its assembly and function in the extrinsic pathway activation complex”,Journal of Biological Chemistry, vol. 266, No. 2, 1991, pp. 915-921.
Abildgaard et al., “The inhibitor of F ViIa in plasma measured with a sensitive chromogenic substrate assay: comparison with antithrombin, protein C and heparin cofactor II in a clinical material”,Folis haematologica; internationals Magazin fur klinische und morpbologische Flutforschung, vol. 115, No. 3, 1988, pp. 274-277.
Sndset et al., “Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)”,Thrombosis Research, vol. 50, No. 60, 1988, pp. 803-813.
Oliver et al., “Active site-inhibited coagulation factor VIIa blocks platelet activation, thrombin generation, and accumulation of platelet-bound factor X in a tissue factor-initiated system”,Blood, vol. 86, No. 10, Suppl. 1, 77A, 1995.
Fareed et al., “Effect of Recombinant Hirudin and Heparin on the Functional and Immunologic Levels of TFPI, Results of Experimental and Clinical Studies”,Blood, vol. 82, No. 10, Suppl. 1, 616a, 1993.
Peterson et al., “Thermal effects on an enzymatically latent conformation of coagulation factor VIIa”,European Journal of Biochemistry, vol. 261, No. 1, 1999, pp. 124-129.
Neuenschwander and Morrissey, “Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa GIa domain is dispensable for binding to tissue factor but important for activation of factor X”,Journal of Biological Chemistry, vol. 269, No. 11, 1994, pp. 8007-8013.
Wildgoose et al., “Identification of calcium binding site in the protease domain of human blood coagulation factor VII: evidence for its role in factor VII-tissue factor interaction”,Biochemistry, vol. 32, No. 1, 1993. pp. 114-119.
Ruf et al., “Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex”,Journal of Biological Chemistry, vol. 267, No. 9, 1992, pp. 6375-6381.
Ieko et al., “The influence of beta2-glycoprotein 1 on tissue factor activity”,Seminars in Thrombosis and Hemostasis, vol. 24, No. 3, 1998, pp. 211-215.
Fiore et al., “An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates”,Blood, vol. 80, No. 12, 1992, pp. 3127-3134.
Kam et al., “Thioester thromogenic substrates for human factor VIIa: Substituted isocoumarins are inhibitors of factor VIIa and in vitro anticoagulants”,Thrombosis and Haemostatis, vol. 64, No. 1, 1990, pp. 133-137.
Sandset et al., “A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions”,Thrombosis Research, vol. 47, No. 4, 1987, pp. 389-400.
Baughman and Lytwyn, “Effect of sera on thrombin activation rate constants: A one-stage assay of the extrinsic system”,Annals of the New York Academy of Sciences, vol. 370, 1981, pp. 822-835.
Tubbs et al., “Procoagulant Activities of Factor VIIa in Haemophilic Plasma”,Br. J. Haematol., vol. 76, Suppl. 1, 1990, p. 33.
Petersen Lars C et al: “Thermal effects on an enzymatically latent conformation of coagulation factor VIIa,” European Journal of Biochemistry, vol. 261, No. 1, Apr. 1999, pp. 124-129, XP0002216886 ISSN: 0014-2956.
Morrissey James H et al: “Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.” Blood, vol. 81, No. 3, 1993, pp. 734-744, XP002216887 ISSN
Chi Liguo
Leadley, Jr. Robert Joseph
Peng Yun-Wen
Bott Cynthia M.
Leary Louise N.
Leon Andrew J.
LandOfFree
Method for direct measurement of coagulation factor VIIa... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for direct measurement of coagulation factor VIIa..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for direct measurement of coagulation factor VIIa... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3307869